(Q45836821)

16 December 2017

title

Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study (English)

1 reference

16 December 2017

author name string

Yan Liu

1

1 reference

16 December 2017

Xiaobei Zhang

2

1 reference

16 December 2017

Jingjing Liu

3

1 reference

16 December 2017

Guofang Hou

4

1 reference

16 December 2017

Sheng Zhang

5

1 reference

16 December 2017

Jin Zhang

6

1 reference

16 December 2017

publication date

8 September 2013

1 reference

16 December 2017

published in

Tumor Biology

1 reference

16 December 2017

volume

35

1 reference

16 December 2017

issue

2

1 reference

16 December 2017

page(s)

1275-1286

1 reference

16 December 2017

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Aromatase inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

The mTOR pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Targeting mTOR pathway: A new concept in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Inhibitor hijacking of Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1170-8

ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24014089

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24014089

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24014089

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-013-1170-8

1 reference

16 December 2017

Dimensions Publication ID

1028280784

0 references

1 reference

16 December 2017